PE20031047A1 - Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama - Google Patents
Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mamaInfo
- Publication number
- PE20031047A1 PE20031047A1 PE2003000493A PE2003000493A PE20031047A1 PE 20031047 A1 PE20031047 A1 PE 20031047A1 PE 2003000493 A PE2003000493 A PE 2003000493A PE 2003000493 A PE2003000493 A PE 2003000493A PE 20031047 A1 PE20031047 A1 PE 20031047A1
- Authority
- PE
- Peru
- Prior art keywords
- patients
- effective amount
- tibolone
- serm
- breast cancer
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 4
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 abstract 4
- 229960001023 tibolone Drugs 0.000 abstract 4
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE AL USO DE UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DE TIBOLONA Y UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DE UN SERM, PARA LA FABRICACION DE UN MEDICAMENTO PARA TRATAR LA DEFICIENCIA DE ESTROGENO RELACIONADA CON LA ENFERMEDAD Y PARA LA PREVENCION DE UNA RECURRENCIA DEL CANCER DE MAMA EN LAS MUJERES QUE SUFREN DE CANCER DE MAMA O ESTAN EN RIESGO DE ELLO, QUIENES EXHIBEN LA DEFICIENCIA DE ESTROGENO RELACIONADA CON LA ENFERMEDAD. DONDE, EL SERM ES TAMOXIFEN, RALOXIFENO. SE REFIERE A UN METODO PARA TRATAR LA DEFICIENCIA DE ESTROGENO, QUE COMPRENDE ADMINISTRAR UNA CANTIDAD FARMACEUTICAMENTE EFECTIVA DE TIBOLONA EN CONJUNTO CON SERM, DONDE LA TIBOLONA SE ADMINISTRA EN UNA DOSIS DIARIA DE 0,3 mg A 2,5 mg. SE REFIERE TAMBIEN A UN EQUIPO PARA TRATAR UNA DEFICIENCIA DE ESTROGENOS, QUE COMPRENDE: 1)UN PRIMER CONTENEDOR QUE COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE TIBOLONA; Y, 2)UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE UN SERM
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02077050 | 2002-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20031047A1 true PE20031047A1 (es) | 2003-12-23 |
Family
ID=29558370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2003000493A PE20031047A1 (es) | 2002-05-24 | 2003-05-20 | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050222100A1 (es) |
EP (1) | EP1511497A1 (es) |
JP (1) | JP2005531575A (es) |
KR (1) | KR20050005490A (es) |
CN (1) | CN1655796A (es) |
AR (1) | AR039843A1 (es) |
AU (1) | AU2003273170A1 (es) |
BR (1) | BR0311146A (es) |
CA (1) | CA2487268A1 (es) |
IL (1) | IL165129A0 (es) |
MX (1) | MXPA04011687A (es) |
PE (1) | PE20031047A1 (es) |
TW (1) | TW200307553A (es) |
WO (1) | WO2003099292A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012623A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
CA2654152A1 (en) | 2006-06-02 | 2007-12-13 | Pear Tree Women's Health Care | Method of treating atrophic vaginitis |
CA2656067C (en) | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
US20110124617A1 (en) * | 2008-05-09 | 2011-05-26 | Lyttle C Richard | Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent |
DE102008057230A1 (de) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin |
WO2011143469A1 (en) | 2010-05-12 | 2011-11-17 | Radius Health,Inc | Therapeutic regimens |
WO2012047617A1 (en) | 2010-09-28 | 2012-04-12 | Radius Health, Inc. | Selective androgen receptor modulators |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP3122426B1 (en) | 2014-03-28 | 2023-01-18 | Duke University | Treating breast cancer using selective estrogen receptor modulators |
CA2984200C (en) | 2015-04-29 | 2024-03-19 | Radius Pharmaceuticals, Inc. | Combinations of rad1901 and a cdk 4/6 inhibitor for treating cancer |
IL292659A (en) | 2016-06-22 | 2022-07-01 | Ellipses Pharma Ltd | Methods for treating breast cancer ar plus |
KR102557321B1 (ko) | 2017-01-05 | 2023-07-18 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
CN112423844B (zh) | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2342145C2 (ru) * | 2000-01-28 | 2008-12-27 | Андорешерш, Инк. | Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами |
US6756480B2 (en) * | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
CN1599606A (zh) * | 2001-07-31 | 2005-03-23 | 辉瑞产品公司 | 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法 |
-
2003
- 2003-05-16 TW TW092113384A patent/TW200307553A/zh unknown
- 2003-05-20 AU AU2003273170A patent/AU2003273170A1/en not_active Abandoned
- 2003-05-20 KR KR10-2004-7018936A patent/KR20050005490A/ko not_active Application Discontinuation
- 2003-05-20 CN CNA038118041A patent/CN1655796A/zh active Pending
- 2003-05-20 MX MXPA04011687A patent/MXPA04011687A/es unknown
- 2003-05-20 CA CA002487268A patent/CA2487268A1/en not_active Abandoned
- 2003-05-20 BR BR0311146-6A patent/BR0311146A/pt not_active IP Right Cessation
- 2003-05-20 PE PE2003000493A patent/PE20031047A1/es not_active Application Discontinuation
- 2003-05-20 JP JP2004506816A patent/JP2005531575A/ja active Pending
- 2003-05-20 US US10/515,712 patent/US20050222100A1/en not_active Abandoned
- 2003-05-20 EP EP03740483A patent/EP1511497A1/en not_active Withdrawn
- 2003-05-20 WO PCT/EP2003/050178 patent/WO2003099292A1/en active Application Filing
- 2003-05-22 AR ARP030101779A patent/AR039843A1/es not_active Application Discontinuation
-
2004
- 2004-11-09 IL IL16512904A patent/IL165129A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN1655796A (zh) | 2005-08-17 |
MXPA04011687A (es) | 2005-03-31 |
WO2003099292A1 (en) | 2003-12-04 |
CA2487268A1 (en) | 2003-12-04 |
IL165129A0 (en) | 2005-12-18 |
JP2005531575A (ja) | 2005-10-20 |
AU2003273170A1 (en) | 2003-12-12 |
BR0311146A (pt) | 2005-03-15 |
US20050222100A1 (en) | 2005-10-06 |
AR039843A1 (es) | 2005-03-02 |
TW200307553A (en) | 2003-12-16 |
KR20050005490A (ko) | 2005-01-13 |
EP1511497A1 (en) | 2005-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
PE20031047A1 (es) | Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama | |
HK1104968A1 (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
MXPA05012810A (es) | Formas de dosis oral de memantina. | |
MX2020012377A (es) | Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades. | |
MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
TNSN07474A1 (en) | Dosage regimen for prasugrel | |
ES2303811T1 (es) | Uso de anastrozol para el tratamiento post-menopausico de una mujer que tiene cancer de mama temprano. | |
AR037390A1 (es) | Formulacion farmaceutica | |
AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion | |
PT1220676E (pt) | Prevencao do cancro colorrectal | |
MX2024001832A (es) | Nueva composicion farmaceutica oral para terapias contra el cancer. | |
CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
MXPA02009603A (es) | Terapias de dosis divididas con actividad de deterioro vascular. | |
MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
MD3121G2 (ro) | Metodă de profilaxie a hepatitei virale B | |
AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
AR015537A1 (es) | Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |